Binimetinib regulatory update

FDA accepted for review an NDA from Array for binimetinib to treat advanced neuroblastoma Ras viral (v-Ras) oncogene (NRAS) mutation-positive melanoma. The PDUFA date is June 30, 2017. Binimetinib is...